Movement Alert｜ZAI LAB Intraday Rise 5.18% in Regular Trading, first clinical data for ZL-1503 set for presentation

Market Focus10-16

On October 16, ZAI LAB posted an Intraday Rise of 5.18% in Regular Trading, trading at HK$18.89, with turnover of HK$44.42 million.

The direct catalyst was the company’s announcement that the first clinical study data for ZL-1503 will be presented for the first time at the annual scientific meeting of the American College of Allergy, Asthma and Immunology.

The planned disclosure covers results from a Phase 1/1b first-in-human study in healthy volunteers, including pharmacokinetic data after single dosing, pharmacodynamic biomarker data related to atopic dermatitis across different dose levels, as well as preliminary safety and immunogenicity data. The move also came amid a broader rally in Hong Kong innovative drug and biotech names, with peers such as Keymed Bio-B, Everest Med and BeOne Medicines also advancing.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment